Top Page
Amplia Therapeutics
(OTC:ATX)
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Amplia Therapeutics Business Overview & Revenue Model
Amplia Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.78M | 3.78M | 4.45M | 1.19M | 1.98M | 1.53M |
| Gross Profit | 3.57M | 3.57M | 4.01M | 1.12M | 1.98M | 1.53M |
| EBITDA | -6.78M | -6.78M | -8.78M | -7.26M | -3.64M | -3.81M |
| Net Income | -6.57M | -6.57M | -4.50M | -6.24M | -3.64M | -2.28M |
Balance Sheet | ||||||
| Total Assets | 22.94M | 22.94M | 14.85M | 18.68M | 24.48M | 10.88M |
| Cash, Cash Equivalents and Short-Term Investments | 10.86M | 10.86M | 3.39M | 9.26M | 14.61M | 1.85M |
| Total Debt | 13.89K | 13.89K | 1.59M | 2.27M | 2.10M | 0.00 |
| Total Liabilities | 1.91M | 1.91M | 3.43M | 2.85M | 2.64M | 539.13K |
| Stockholders Equity | 21.02M | 21.02M | 11.42M | 15.84M | 21.85M | 10.34M |
Cash Flow | ||||||
| Free Cash Flow | -6.89M | -6.89M | -5.13M | -5.31M | -4.42M | -2.92M |
| Operating Cash Flow | -6.89M | -6.89M | -5.13M | -5.29M | -4.40M | -2.92M |
| Investing Cash Flow | -2.07K | -2.07K | -2.23K | -58.42K | -26.64K | -5.35K |
| Financing Cash Flow | 14.32M | 14.32M | -772.98K | -84.22K | 17.19M | 3.66M |
Amplia Therapeutics Technical Analysis
Amplia Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$14.28M | ― | -143.71% | ― | 306.88% | ― | |
| ― | AU$69.26M | ― | -41.60% | ― | ― | 4.07% | |
| ― | AU$16.40M | -7.65 | -1651.76% | ― | -100.00% | 2.86% | |
| ― | AU$6.62M | ― | -628.72% | ― | ― | 31.87% | |
| ― | AU$27.18M | -5.57 | -157.93% | ― | ― | -36.89% |
Amplia Therapeutics Corporate Events
Amplia Therapeutics has reported significant progress in its clinical trials for narmafotinib, a FAK inhibitor, showing improved outcomes in metastatic pancreatic cancer treatment. The company has achieved key regulatory milestones, including ethics approval for a new trial combining narmafotinib with FOLFIRINOX chemotherapy and securing a patent for its drug formulation, positioning it for further commercial development and potential partnerships.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has received a $3.77 million R&D tax rebate from the Australian Tax Office, which will support the progression of its clinical trials for narmafotinib, a FAK inhibitor. This funding will aid in advancing the ACCENT and AMPLICITY trials, which are exploring narmafotinib’s effectiveness in treating advanced pancreatic cancer, potentially enhancing Amplia’s position in the oncology pharmaceutical industry.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics is expanding its U.S. presence by increasing investor engagement and awareness through a capital markets campaign. This initiative supports its ongoing Phase 2A clinical trial for pancreatic cancer and includes plans to uplist to the OTCQB market, aiming to broaden its U.S. investor base and enhance its market positioning.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has announced promising results from its ACCENT clinical trial, which tests the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has shown an improved Objective Response Rate of 33% compared to 23% with chemotherapy alone, and a mean duration on trial of 219 days, indicating enhanced efficacy and durability. Narmafotinib continues to demonstrate good tolerability, with no significant increase in chemotherapy-related side effects, positioning Amplia favorably in the cancer treatment landscape.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited announced the cessation of 5,626,000 securities due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategies and future growth prospects.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has announced that the US Patent Office has allowed a key patent for its FAK inhibitor, narmafotinib, with a formal grant expected soon. This patent, already granted in several countries, extends narmafotinib’s protection until at least 2040, enhancing its commercial value. The patent describes a stable form of narmafotinib, which is being used in clinical trials for advanced pancreatic cancer, showing promising results. This development strengthens Amplia’s intellectual property portfolio and positions the company favorably in the pharmaceutical industry, particularly in the field of cancer treatment.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited announced a change in the director’s interest for Dr. Warwick Tong, as reflected in the attached Appendix 3Y. This update involves changes in the allotment and expiry of shares and options held by Dr. Tong. Such changes in director’s interests can impact stakeholder perceptions and reflect internal strategic adjustments within the company.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced a change in the director’s interest notice for Dr. Christopher Burns, reflecting updates in his securities holdings. This announcement, authorized by the company’s secretary, highlights the ongoing management and regulatory compliance within the company, potentially impacting investor perceptions and stakeholder confidence.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited announced a change in the director’s interest notice for Dr. Robert Peach, reflecting a recent allotment of shares and options, as well as the expiry of certain options. This update is part of the company’s regulatory compliance and may impact the company’s stock dynamics and stakeholder interests.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced a change in the director’s interest notice for Jane Bell, reflecting recent changes in her holdings of shares and options. This update is part of the company’s ongoing compliance with ASX listing rules and demonstrates transparency in its corporate governance practices.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced the cessation of 2,355,000 securities due to the expiry of options or other convertible securities without exercise or conversion. This announcement may impact the company’s capital structure but does not indicate any immediate operational changes or strategic shifts.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has commenced a new pancreatic cancer trial, enrolling its first patient to test the combination of its FAK inhibitor, narmafotinib, with the chemotherapy regimen FOLFIRINOX. This trial, taking place in Australia and the US, aims to assess the safety, tolerability, and pharmacokinetics of narmafotinib, with dose-escalation expected to complete by Q1 2026. The trial’s initiation marks a significant milestone in the development of narmafotinib, which has shown promising results in preclinical studies and aims to improve survival rates in pancreatic cancer patients.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced the cessation of 1,000,000 securities due to the expiry of options without exercise or conversion, effective September 2, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth potential.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has announced that the United States Adopted Names (USAN) Council has approved ‘narmafotinib’ as the nonproprietary name for its lead FAK inhibitor, which is undergoing clinical trials for pancreatic cancer. This approval is a critical milestone in the drug’s commercial development, coinciding with the initiation of a clinical trial combining narmafotinib with FOLFIRINOX chemotherapy in the USA and Australia. The trial aims to explore the drug’s safety, tolerability, and efficacy, potentially enhancing Amplia’s positioning in the oncology market.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced the issuance of new unquoted equity securities, specifically options expiring on September 30, 2028, with an exercise price of $0.30. This move is part of an employee incentive scheme, which may enhance employee retention and motivation, potentially impacting the company’s operational dynamics and stakeholder interests positively.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has successfully raised approximately $2.735 million through the issuance of 11,891,307 fully paid ordinary shares, following shareholder approval. This capital injection supports ongoing clinical trials of their promising FAK inhibitor, narmafotinib, which has shown efficacy in treating advanced pancreatic cancer. The trials, conducted in Australia and the US, aim to optimize dosing and further establish the drug’s effectiveness in combination with chemotherapy regimens, potentially enhancing Amplia’s position in the oncology market.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced the quotation of 1,021,740 new ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code ATX, effective from September 1, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced the quotation of 10,869,567 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code ATX, effective September 1, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which could positively impact its strategic initiatives and stakeholders.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has initiated a new clinical trial in Australia to test the combination of its FAK inhibitor, narmafotinib, with the chemotherapy regimen FOLFIRINOX in patients with newly diagnosed metastatic pancreatic cancer. This trial, which is also set to commence in the USA, aims to explore the safety, tolerability, and efficacy of this combination, potentially offering improved outcomes for patients. The trial’s initiation underscores Amplia’s strategic focus on fibrotic cancers and its commitment to advancing innovative therapies in oncology.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited announced that all resolutions proposed at its Annual General Meeting were successfully passed. The company is advancing its ACCENT trial, which investigates the efficacy of its FAK inhibitor, narmafotinib (AMP945), in combination with other drugs for pancreatic cancer. This development could enhance Amplia’s position in the pharmaceutical industry, particularly in cancer treatment, and potentially benefit stakeholders by advancing treatment options for pancreatic cancer.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has released a presentation by its CEO at the Annual General Meeting, highlighting the progress of its drug narmafotinib (AMP945), a FAK inhibitor showing promise in preclinical cancer studies. The ACCENT trial is currently assessing the drug’s efficacy in combination with other treatments for pancreatic cancer, with the trial being conducted across sites in Australia and South Korea.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has released a presentation at the Bioshares Biotech Summit, highlighting their focus on targeting pancreatic cancer through their pipeline of Focal Adhesion Kinase (FAK) inhibitors. This strategic move underscores the company’s commitment to advancing treatments for fibrotic cancers and could potentially enhance its position in the biotech industry by addressing significant unmet medical needs.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has announced positive interim data from its ACCENT trial, which is evaluating the efficacy of its FAK inhibitor, narmafotinib, in combination with standard chemotherapies for advanced pancreatic cancer. The trial results show significant improvements in progression-free survival and objective response rates compared to chemotherapy alone, indicating a promising advancement in treatment options for pancreatic cancer patients. The company is preparing for a potential pivotal phase 2b/3 trial, which could enhance its position in the oncology market and offer new hope for stakeholders in the healthcare sector.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced a Share Purchase Plan (SPP) to raise $2.5 million, with the potential to accept over-subscriptions up to an additional $7.5 million. The SPP, which is not underwritten, is conditional on shareholder approval and is managed by Bell Potter Securities Limited. This move is part of Amplia’s strategic efforts to enhance its financial position and support its ongoing operations, potentially impacting its market standing and offering new opportunities for eligible shareholders and institutional investors.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics Limited has announced a change in its registered office and principal place of business to Level 5, 90 William Street, Melbourne VIC 3000. This move is a strategic decision for the company, which is actively advancing its pipeline of FAK inhibitors. The change in location could potentially enhance operational efficiency and align with the company’s focus on developing treatments for fibrotic cancers and chronic diseases, thereby impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has reported significant progress in its ACCENT trial, demonstrating a 31% response rate for its FAK inhibitor narmafotinib combined with chemotherapy, surpassing the 23% rate of chemotherapy alone. The company is also initiating a new trial combining narmafotinib with FOLFIRINOX chemotherapy in the USA and Australia, supported by a recent $27.5 million capital raise to fund operations through 2027.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
Amplia Therapeutics has received Australian ethics clearance to initiate a Phase 2 clinical trial of its FAK inhibitor, narmafotinib, in combination with FOLFIRINOX chemotherapy for advanced pancreatic cancer patients. This trial, which follows US ethics approval, aims to identify the optimal dose of narmafotinib and will be conducted at sites in Australia and the USA. The trial’s outcome could enhance Amplia’s position in the oncology sector by potentially offering a more effective treatment option for pancreatic cancer, thereby impacting stakeholders positively.